A phase I study of pembrolizumab with maraviroc is ongoing in patients with colorectal cancer; A phase II study of vicriviroc in combination with pembrolizumab is ongoing in patients with advanced metastatic MSS-colorectal cancer; and a phase Ib/II study of carboplatin and leronlimab is designed for patients with CCR5+ metastatic triple negative breast cancer (Jiao et al., 2019). The gene discussed is CCR5; the disease is colorectal cancer.